JP2025013513A5 - - Google Patents

Info

Publication number
JP2025013513A5
JP2025013513A5 JP2024194079A JP2024194079A JP2025013513A5 JP 2025013513 A5 JP2025013513 A5 JP 2025013513A5 JP 2024194079 A JP2024194079 A JP 2024194079A JP 2024194079 A JP2024194079 A JP 2024194079A JP 2025013513 A5 JP2025013513 A5 JP 2025013513A5
Authority
JP
Japan
Prior art keywords
compound
modified
internucleoside linkage
sugar
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024194079A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025013513A (ja
Filing date
Publication date
Priority claimed from PCT/US2019/033244 external-priority patent/WO2019226611A1/en
Application filed filed Critical
Publication of JP2025013513A publication Critical patent/JP2025013513A/ja
Publication of JP2025013513A5 publication Critical patent/JP2025013513A5/ja
Pending legal-status Critical Current

Links

JP2024194079A 2018-05-22 2024-11-06 Ａｐｏｌ１発現のモジュレーター Pending JP2025013513A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862674865P 2018-05-22 2018-05-22
US62/674,865 2018-05-22
PCT/US2019/033244 WO2019226611A1 (en) 2018-05-22 2019-05-21 Modulators of apol1 expression
JP2020565431A JP7247227B2 (ja) 2018-05-22 2019-05-21 Ａｐｏｌ１発現のモジュレーター
JP2023040313A JP7645301B2 (ja) 2018-05-22 2023-03-15 Ａｐｏｌ１発現のモジュレーター

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2023040313A Division JP7645301B2 (ja) 2018-05-22 2023-03-15 Ａｐｏｌ１発現のモジュレーター

Publications (2)

Publication Number Publication Date
JP2025013513A JP2025013513A (ja) 2025-01-24
JP2025013513A5 true JP2025013513A5 (https=) 2025-08-20

Family

ID=68613945

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020565431A Active JP7247227B2 (ja) 2018-05-22 2019-05-21 Ａｐｏｌ１発現のモジュレーター
JP2023040313A Active JP7645301B2 (ja) 2018-05-22 2023-03-15 Ａｐｏｌ１発現のモジュレーター
JP2024194079A Pending JP2025013513A (ja) 2018-05-22 2024-11-06 Ａｐｏｌ１発現のモジュレーター

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2020565431A Active JP7247227B2 (ja) 2018-05-22 2019-05-21 Ａｐｏｌ１発現のモジュレーター
JP2023040313A Active JP7645301B2 (ja) 2018-05-22 2023-03-15 Ａｐｏｌ１発現のモジュレーター

Country Status (27)

Country Link
US (4) US10927377B2 (https=)
EP (1) EP3799570A4 (https=)
JP (3) JP7247227B2 (https=)
KR (2) KR20250153881A (https=)
CN (3) CN118127020A (https=)
AR (1) AR115416A1 (https=)
AU (2) AU2019274461B2 (https=)
BR (1) BR112020023436A2 (https=)
CA (1) CA3099750A1 (https=)
CL (1) CL2020003010A1 (https=)
CO (1) CO2020015377A2 (https=)
CR (1) CR20200631A (https=)
EA (1) EA202092748A1 (https=)
EC (1) ECSP20082339A (https=)
IL (2) IL278785B2 (https=)
JO (1) JOP20200291A1 (https=)
MA (1) MA53924A (https=)
MX (2) MX2020012497A (https=)
MY (1) MY200352A (https=)
NI (1) NI202000085A (https=)
PE (1) PE20211397A1 (https=)
PH (1) PH12020551995A1 (https=)
SG (1) SG11202011397QA (https=)
TW (2) TWI841564B (https=)
UA (1) UA128819C2 (https=)
WO (1) WO2019226611A1 (https=)
ZA (1) ZA202007537B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE49076E1 (en) 2010-04-18 2022-05-17 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for treating renal disease
MA53924A (fr) 2018-05-22 2021-08-25 Ionis Pharmaceuticals Inc Modulateurs de l'expression d'apol1
TWI848031B (zh) 2018-12-17 2024-07-11 美商維泰克斯製藥公司 Apol1抑制劑及其使用方法
WO2021154997A1 (en) 2020-01-29 2021-08-05 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
CA3185604A1 (en) 2020-06-12 2021-12-16 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and use of the same
WO2021252863A1 (en) 2020-06-12 2021-12-16 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and using the same
IL314330A (en) 2022-01-18 2024-09-01 Maze Therapeutics Inc Apol1 inhibitors and methods of use
US20260055083A1 (en) * 2022-08-19 2026-02-26 Maze Therapeutics, Inc. Apol1 inhibitors and methods of use
TW202545540A (zh) 2024-05-21 2025-12-01 瑞典商阿斯特捷利康公司 用於治療ａｐｏｌ１介導之腎病之方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020082401A1 (en) 1994-12-15 2002-06-27 Yeda Research And Development Company Modulators of the function of FAS/APO1 receptors
US6833361B2 (en) * 1998-05-26 2004-12-21 Ribapharm, Inc. Nucleosides having bicyclic sugar moiety
WO2002028999A2 (en) 2000-10-03 2002-04-11 Gene Logic, Inc. Gene expression profiles in granulocytic cells
USH2191H1 (en) 2000-10-24 2007-06-05 Snp Consortium Identification and mapping of single nucleotide polymorphisms in the human genome
US20070054278A1 (en) 2003-11-18 2007-03-08 Applera Corporation Polymorphisms in nucleic acid molecules encoding human enzyme proteins, methods of detection and uses thereof
US20050171044A1 (en) 2003-12-24 2005-08-04 Stein David A. Oligonucleotide compound and method for treating nidovirus infections
EP2397563A3 (en) 2004-09-17 2012-07-18 Isis Pharmaceuticals, Inc. Enhanced antisense oligonucleotides
EP1867338A1 (en) 2006-05-30 2007-12-19 Université Libre De Bruxelles Pharmaceutical composition comprising apolipoproteins for the treatment of human diseases
JP2010507387A (ja) * 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド 新規のｓｉＲＮＡおよびその使用方法
WO2010040112A2 (en) 2008-10-03 2010-04-08 Curna, Inc. Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1
EP2370580B1 (en) 2008-12-04 2019-09-11 CuRNA, Inc. Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1
WO2011020865A1 (en) 2009-08-18 2011-02-24 Universite Libre De Bruxelles Apolipoprotein l- i variants and their use
AU2010319314C1 (en) 2009-11-13 2016-09-01 Sarepta Therapeutics, Inc. Antisense antiviral compound and method for treating influenza viral infection
RU2619185C2 (ru) 2009-12-23 2017-05-12 Курна, Инк. Лечение заболеваний, связанных с разобщающим белком 2 (ucp2), путем ингибирования природного антисмыслового транскрипта к ucp2
US9023355B2 (en) 2010-04-13 2015-05-05 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for treating renal disease
US20120003644A1 (en) 2010-06-07 2012-01-05 Rappaport Family Institute For Research In The Medical Sciences Methods and kits for determining predisposition to develop kidney diseases
HK1205189A1 (en) 2012-02-08 2015-12-11 Isis Pharmaceuticals, Inc. Methods and compositions for modulating factor vii expression
RU2748495C2 (ru) 2012-05-24 2021-05-26 Ионис Фармасьютикалз, Инк. Способы и композиции для модулирования экспрессии аполипопротеина (а)
EP2920206A4 (en) 2012-11-16 2016-07-06 Merck Sharp & Dohme MODIFIED APOL1 POLYPEPTIDE
US10130632B2 (en) * 2012-11-27 2018-11-20 Beth Israel Deaconess Medical Center, Inc. Methods for treating renal disease
EP2972381A2 (en) 2013-03-14 2016-01-20 Galapagos NV Molecular targets and compounds, and methods to identify the same, useful in the treatment of diseases associated with epithelial mesenchymal transition
GB201311057D0 (en) 2013-06-21 2013-08-07 Univ Greenwich Antisense oligonucleotide compositions
TWI772856B (zh) * 2013-07-19 2022-08-01 美商百健Ｍａ公司 用於調節τ蛋白表現之組合物
WO2015136509A2 (en) 2014-03-14 2015-09-17 Genesis Theranostix Korlatolt Felelossegu Tarsasag Diagnostic and therapeutic targets for preeclampsia and closely related complications of pregnancy
CN106103717A (zh) 2014-03-19 2016-11-09 Ionis制药公司 用于调节共济失调蛋白2表达的组合物
EP3020813A1 (en) 2014-11-16 2016-05-18 Neurovision Pharma GmbH Antisense-oligonucleotides as inhibitors of TGF-R signaling
TW201718010A (zh) 2015-06-19 2017-06-01 健臻公司 治療原發性局部節段性腎小球硬化症之方法
CA2991045A1 (en) 2015-06-29 2017-01-05 Caris Science, Inc. Therapeutic oligonucleotides binding c1q
JP6877414B2 (ja) 2015-09-24 2021-05-26 アイオニス・ファーマシューティカルズ・インコーポレイテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｋｒａｓ発現のモジュレーター
MA53924A (fr) 2018-05-22 2021-08-25 Ionis Pharmaceuticals Inc Modulateurs de l'expression d'apol1

Similar Documents

Publication Publication Date Title
JP2025013513A5 (https=)
FI119416B (fi) L-nukleosidejä hepatiitti-B-viruksen ja Epstein-Barr-viruksen hoitamiseksi
Ma et al. Structure− Activity Relationships of 1-(2-Deoxy-2-fluoro-β-l-arabino-furanosyl) pyrimidine Nucleosides as Anti-Hepatitis B Virus Agents
AU784374C (en) Synthesis of 2'-deoxy-L-nucleosides
EP1411954B1 (en) Modified nucleosides for treatment of viral infections and abnormal cellular proliferation
CA2184375C (en) Oligonucleotide n3'-p5' phosphoramidates: synthesis and compounds; hybridization and nuclease resistance properties
EP1984381B1 (en) 6-modified bicyclic nucleic acid analogs
US5696253A (en) Polynucleoside chain with 3'→5' guanidyl linkages
JP2021525084A5 (https=)
US5753789A (en) Oligonucleotides containing L-nucleosides
JPH0898700A (ja) 遺伝子発現を検出及び変調する糖修飾されたオリゴヌクレオチド
EP2173760A2 (en) Carbocyclic bicyclic nucleic acid analogs
JPH08508491A (ja) ホスホジエステル結合をアミド結合に置き換えたオリゴヌクレオチド
CN1292795A (zh) 特定的二核苷酸和它们作为粘膜纤毛清除和纤毛颤动频率调节剂的应用
US5808040A (en) L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
Génu-Dellac et al. Systematic synthesis and antiviral evaluation of α-L-arabinofuranosyl and 2′-Deoxy-α-L-erythro-pento-furanosyl nucleosides of the five naturally occurring nucleic acid bases
JPWO2019226611A5 (https=)
CN114456169B (zh) 3′-脱氧-3′,4′-二脱氢核糖核苷类似物及其制备方法
JPWO2019140452A5 (https=)
JPWO2020205463A5 (https=)
JPWO2023097291A5 (https=)
JPWO2022072244A5 (https=)
JPWO2022109139A5 (https=)
JPWO2020206115A5 (https=)
HK1014716B (en) L-nucleosides for the treatment of hepatitis b-virus and epstein-bar virus